Element Biosciences Looks to Go Beyond Just Sequencing with AVITI

episode

Vanguards of Healthcare by Bloomberg Intelligence not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Vanguards of Healthcare by Bloomberg Intelligence

Athenahealth's Strategic Reset, Push for Speed in Ambulatory Care 53 min · 02 Apr 2026

Inside Insilico Medicine’s AI Strategy and Lilly Breakthrough 1h 2m · 31 Mar 2026

Abridge Moving AI From Scribing to Clinical Workflows 54 min · 26 Mar 2026

7Wire's Jaffee on the Hard Truths Behind Health-Tech Investing 44 min · 19 Mar 2026

Xaira’s War on Trial-and-Error Drug Development 56 min · 12 Mar 2026

AVS’ Toland on Next Lithotripsy Launch 43 min · 05 Mar 2026

All episodes from Vanguards of Healthcare by Bloomberg Intelligence →

Report any issue

Source

Recorded15 Feb 2024

Publisheromnycontent.com ↗

Handlerec:13806606

Show notes

“We started this company looking at the current genomics field and evaluating the gap we’re trying to fill,” Molly He, CEO and co-founder of Element Biosciences, explains to Bloomberg Intelligence. Dr. He joins BI analyst Jonathan Palmer on this Vanguards of Health Care podcast episode to discuss the intricacies of building a new gene-sequencing instrument from scratch, the challenges of getting customers to adopt technology from new entrants and why the extension of the AVITI system beyond DNA into protein and cellular analysis is so important.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in